Spreafico, Anna

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

Shen, S. Y., Singhania, R., Fehringer, G., Chakravarthy, A., Roehrl, M. H. A., Chadwick, D., Zuzarte, P. C., Borgida, A., Wang, T. T., Li, T., et al. (2018) · Nature

Cancer Genomics and DiagnosticsEpigenetics and DNA Methylation

Cited by 983

Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., Razak, A. A., Shchegrova, S., et al. (2020) · Nature Cancer

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 487

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 232

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

Meric-Bernstam, F., Sandhu, S. K., Hamid, O., Spreafico, A., Kasper, S., Dummer, R., Shimizu, T., Steeghs, N., Lewis, N., Talluto, C. C., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 190

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

Spreafico, A., Heirali, A. A., Araujo, D. V., Tan, T. J., Oliva, M., Schneeberger, P. H. H., Chen, B., Wong, M. K., Stayner, L.-A., Hansen, A. R., et al. (2023) · Annals of Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 96

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

Kanjanapan, Y., Day, D., Butler, M. O., Wang, L., Joshua, A. M., Hogg, D., Leighl, N. B., Razak, A. R. A., Hansen, A. R., Boujos, S., et al. (2019) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 72

Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics

Araujo, D. V., Watson, G. A., Oliva, M., Heirali, A., Coburn, B., Spreafico, A., & Siu, L. L. (2021) · Cancer Treatment Reviews

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 29

Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival

Spreafico, A., Coate, L., Zhai, R., Xu, W., Chen, Z.-F., Chen, Z., Patel, D., Tse, B., Brown, M. C., Heist, R. S., et al. (2017) · Cancer Epidemiology

Esophageal Cancer Research and TreatmentHead and Neck Cancer Studies

Cited by 19